Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer

[1]  M. Dowsett,et al.  Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer , 2019, npj Breast Cancer.

[2]  I. Ellis,et al.  Heterogeneity of tumour‐infiltrating lymphocytes in breast cancer and its prognostic significance , 2018, Histopathology.

[3]  Yunlong Liu,et al.  Normal Breast-Derived Epithelial Cells with Luminal and Intrinsic Subtype-Enriched Gene Expression Document Interindividual Differences in Their Differentiation Cascade. , 2018, Cancer research.

[4]  Renzo Boldorini,et al.  FOXA1 and AR in invasive breast cancer: new findings on their co-expression and impact on prognosis in ER-positive patients , 2018, BMC Cancer.

[5]  I. Ellis,et al.  The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours , 2018, Breast Cancer Research.

[6]  S. Linnarsson,et al.  Exome sequencing of primary breast cancers with paired metastatic lesions reveals metastasis-enriched mutations in the A-kinase anchoring protein family (AKAPs) , 2018, BMC Cancer.

[7]  Emad A. Rakha,et al.  Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine , 2018, Pathobiology.

[8]  Sandip K. Mishra,et al.  A novel FOXA1/ESR1 interacting pathway: A study of Oncomine™ breast cancer microarrays , 2017, Oncology letters.

[9]  I. Ellis,et al.  Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections , 2017, Breast Cancer Research and Treatment.

[10]  J. Carroll.  Mechanisms of oestrogen receptor (ER) gene regulation in breast cancer , 2016, European journal of endocrinology.

[11]  Bin Liu,et al.  Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes , 2016, Nature Communications.

[12]  John M S Bartlett,et al.  Updated UK Recommendations for HER2 assessment in breast cancer , 2014, Journal of Clinical Pathology.

[13]  Anthony Rhodes,et al.  Estrogen and progesterone receptors in breast cancer. , 2014, Future oncology.

[14]  P. Kille,et al.  A mechanism for epithelial–mesenchymal transition and anoikis resistance in breast cancer triggered by zinc channel ZIP6 and STAT3 (signal transducer and activator of transcription 3) , 2013, The Biochemical journal.

[15]  Guy N Brock,et al.  Interrogating differences in expression of targeted gene sets to predict breast cancer outcome , 2013, BMC Cancer.

[16]  Feng Xie,et al.  Negative Correlation of LIV-1 and E-Cadherin Expression in Hepatocellular Carcinoma Cells , 2013, PloS one.

[17]  V. Theodorou,et al.  GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility , 2013, Genome research.

[18]  R. García-Becerra,et al.  Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance , 2012, International journal of molecular sciences.

[19]  H. Freake,et al.  Zinc and Cancer: Implications for LIV-1 in Breast Cancer , 2012, Nutrients.

[20]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[21]  M. Campone,et al.  bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer , 2012, Breast Cancer Research and Treatment.

[22]  R. Vessella,et al.  LIV-1 Promotes Prostate Cancer Epithelial-to-Mesenchymal Transition and Metastasis through HB-EGF Shedding and EGFR-Mediated ERK Signaling , 2011, PloS one.

[23]  V. López,et al.  Zip6-attenuation promotes epithelial-to-mesenchymal transition in ductal breast tumor (T47D) cells. , 2010, Experimental cell research.

[24]  F. Motoi,et al.  LIV-1 enhances the aggressive phenotype through the induction of epithelial to mesenchymal transition in human pancreatic carcinoma cells. , 2009, International journal of oncology.

[25]  Hui Shen,et al.  Concordant correlation of LIV-1 and E-cadherin expression in human breast cancer cell MCF-7 , 2009, Molecular Biology Reports.

[26]  K. Taylor.  A distinct role in breast cancer for two LIV-1 family zinc transporters. , 2008, Biochemical Society transactions.

[27]  G. Ball,et al.  Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. , 2008, European journal of cancer.

[28]  T. Nielsen,et al.  GATA-3 Expression in Breast Cancer Has a Strong Association with Estrogen Receptor but Lacks Independent Prognostic Value , 2008, Cancer Epidemiology Biomarkers & Prevention.

[29]  K. Taylor,et al.  LIV-1 suppression inhibits HeLa cell invasion by targeting ERK1/2-Snail/Slug pathway. , 2007, Biochemical and biophysical research communications.

[30]  Ian O Ellis,et al.  The Emerging Role of the LIV-1 Subfamily of Zinc Transporters in Breast Cancer , 2007, Molecular medicine.

[31]  Zena Werb,et al.  GATA-3 Maintains the Differentiation of the Luminal Cell Fate in the Mammary Gland , 2006, Cell.

[32]  S. Vacher,et al.  Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. , 2006, Endocrine-related cancer.

[33]  F. Vizoso,et al.  Cytosolic levels of TFF1/pS2 in breast cancer: their relationship with clinical–pathological parameters and their prognostic significance , 2006, Breast Cancer Research and Treatment.

[34]  Armin A. Weiser,et al.  Expression levels of the putative zinc transporter LIV‐1 are associated with a better outcome of breast cancer patients , 2005, International journal of cancer.

[35]  G. Ball,et al.  High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.

[36]  A. Harris,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British Journal of Cancer.

[37]  D G Altman,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British journal of cancer.

[38]  B. Bay,et al.  A Novel Antiestrogenic Mechanism in Progesterone Receptor-transfected Breast Cancer Cells* , 2005, Journal of Biological Chemistry.

[39]  R. Nicholson,et al.  Zinc transporter LIV-1: a link between cellular development and cancer progression , 2004, Trends in Endocrinology & Metabolism.

[40]  D. Rimm,et al.  X-Tile , 2004, Clinical Cancer Research.

[41]  R. Nicholson,et al.  Structure-function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of zinc transporters. , 2003, The Biochemical journal.

[42]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[43]  R. Ruffin,et al.  The role of zinc in caspase activation and apoptotic cell death , 2001, Biometals.

[44]  D. Eide,et al.  Eukaryotic zinc transporters and their regulation , 2001, Biometals.

[45]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[46]  I. Ellis,et al.  Oestrogen-regulated genes in breast cancer: association of pLIV1 with response to endocrine therapy. , 1998, British Journal of Cancer.

[47]  E B Cox,et al.  Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. , 1985, Archives of pathology & laboratory medicine.

[48]  R. Vihko,et al.  Estrogen and Progesterone Receptors in Breast Cancer , 1981, Acta obstetricia et gynecologica Scandinavica. Supplement.

[49]  I. Ellis,et al.  The Nottingham prognostic index in primary breast cancer , 2005, Breast Cancer Research and Treatment.